KR20210151188A - 뼈 및 관절 감염증의 치료 및 예방 방법 - Google Patents

뼈 및 관절 감염증의 치료 및 예방 방법 Download PDF

Info

Publication number
KR20210151188A
KR20210151188A KR1020217036829A KR20217036829A KR20210151188A KR 20210151188 A KR20210151188 A KR 20210151188A KR 1020217036829 A KR1020217036829 A KR 1020217036829A KR 20217036829 A KR20217036829 A KR 20217036829A KR 20210151188 A KR20210151188 A KR 20210151188A
Authority
KR
South Korea
Prior art keywords
gly
val
ala
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217036829A
Other languages
English (en)
Korean (ko)
Inventor
레이먼드 슈흐
Original Assignee
콘트라펙트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘트라펙트 코포레이션 filed Critical 콘트라펙트 코포레이션
Publication of KR20210151188A publication Critical patent/KR20210151188A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217036829A 2019-04-11 2020-04-10 뼈 및 관절 감염증의 치료 및 예방 방법 Pending KR20210151188A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962832754P 2019-04-11 2019-04-11
US62/832,754 2019-04-11
US201962849672P 2019-05-17 2019-05-17
US62/849,672 2019-05-17
US201962938812P 2019-11-21 2019-11-21
US62/938,812 2019-11-21
US202062964755P 2020-01-23 2020-01-23
US62/964,755 2020-01-23
PCT/US2020/027752 WO2020210691A1 (en) 2019-04-11 2020-04-10 Method of treating and preventing bone and joint infections

Publications (1)

Publication Number Publication Date
KR20210151188A true KR20210151188A (ko) 2021-12-13

Family

ID=72752118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036829A Pending KR20210151188A (ko) 2019-04-11 2020-04-10 뼈 및 관절 감염증의 치료 및 예방 방법

Country Status (11)

Country Link
US (1) US20220193186A1 (https=)
EP (1) EP3980049A4 (https=)
JP (1) JP2022526624A (https=)
KR (1) KR20210151188A (https=)
CN (1) CN114025783A (https=)
AU (1) AU2020271116A1 (https=)
BR (1) BR112021019884A2 (https=)
CA (1) CA3136461A1 (https=)
IL (1) IL286994A (https=)
MX (1) MX2021012375A (https=)
WO (1) WO2020210691A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081691A1 (en) * 2021-11-04 2023-05-11 Contrafect Corporation Method of treating and preventing bone and joint infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
KR20210121313A (ko) * 2012-05-09 2021-10-07 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
KR20200023521A (ko) * 2012-05-09 2020-03-04 콘트라펙트 코포레이션 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR20190004799A (ko) * 2016-05-12 2019-01-14 콘트라펙트 코포레이션 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법
KR20200124724A (ko) * 2018-02-26 2020-11-03 콘트라펙트 코포레이션 변형된 PlySs2 리신 및 이의 용도
CN112867398A (zh) * 2018-06-22 2021-05-28 康特拉费克特公司 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感

Also Published As

Publication number Publication date
CA3136461A1 (en) 2020-10-15
WO2020210691A1 (en) 2020-10-15
AU2020271116A1 (en) 2021-11-11
BR112021019884A2 (pt) 2022-01-18
IL286994A (en) 2021-12-01
JP2022526624A (ja) 2022-05-25
EP3980049A4 (en) 2023-07-19
US20220193186A1 (en) 2022-06-23
EP3980049A1 (en) 2022-04-13
CN114025783A (zh) 2022-02-08
MX2021012375A (es) 2021-11-17

Similar Documents

Publication Publication Date Title
EP3091992B1 (en) Phage therapy of e coli infections
CN116077630A (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
JP2024010053A (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
KR20010022237A (ko) 리소스타핀을 단독 또는 항생제와의 조합으로 포함하는포도상구균 감염 치료용 약제학적 조성물
IL97344A (en) Synergistic compositions containing béta-lactam antibiotics and cationic oligopeptides for treating infections
KR20140142700A (ko) 항균성 펩티드
KR20210024005A (ko) 스태필로코커스 아우레우스 및 그람 양성 세균을 항생제에 재민감화시키기 위한 리신 및 이의 유도체
CN105963680B (zh) 用于抑制/瓦解生物被膜的抑制剂及其应用
JP2021513865A (ja) 修飾ＰｌｙＳｓ２溶解素及びその使用
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
JP2025512749A (ja) 感染症の新しい治療法
KR20210151188A (ko) 뼈 및 관절 감염증의 치료 및 예방 방법
KR20230162045A (ko) 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물
CN116406282A (zh) 具有针对多药耐药性病原体的抗微生物活性的肽实体
JP2022526978A (ja) ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
US20220160842A1 (en) Method of treating infective endocarditis
RU2715694C1 (ru) Фармацевтическая композиция для лечения глазных инфекций, вызванных метициллин-устойчивыми штаммами Staphylococcus aureus, включающая в качестве активного начала N-концевой CHAP-домен эндолизина бактериофага K Staphylococcus aureus
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
EP3328412B1 (en) Antimicrobial peptide for nosocomial infections
WO2023081691A1 (en) Method of treating and preventing bone and joint infections
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2804774C2 (ru) Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾ＰｌｙＳｓ２溶解素及び抗生物質の組合せ
CN115209912A (zh) 肽组合物及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T12 Administrative time limit extension not granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T12-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000